Durable Medical Equipment Market Size & Share 2026-2035

Durable Medical Equipment Market Size

The global durable medical equipment market was valued at USD 265.2 billion in 2025, underpinned by broad-based demand across home healthcare settings, hospital procurement programs, ambulatory surgical centers, and long-term care facilities worldwide. The market is forecast to reach USD 478.1 billion by 2035, advancing at a compound annual growth rate (CAGR) of 6.1% over the 2026 to 2035 period, according to the latest report published by Global Market Insights Inc.

This growth trajectory reflects the convergence of aging demographics, accelerating chronic disease prevalence, and sustained institutional investment in decentralized care delivery models across both developed and emerging economies.

 

The transition from episodic hospital-based care to continuous community and home-based care management is reshaping procurement patterns, expanding the addressable patient population for DME, and reinforcing demand across product categories ranging from catheters and consumables to connected monitoring platforms and mobility solutions.

Key Drivers

Drivers Impact Analysis

Driver	Impact on CAGR Forecast	Geographic Relevance	Impact Timeline
Rising patient preference for home-based care	1.8%	North America, Europe, Asia Pacific	Medium term (2–4 years)
Increasing prevalence of chronic diseases globally	1.1%	Global, with emphasis on emerging markets	Long term (≥ 4 years)
Growing geriatric population	0.9%	Asia Pacific, North America, Europe	Long term (4 years and above)
Technological advancements in products	1.4%	North America, Europe	Medium term (2 to 4 years)

Rising Patient Preference for Home-Based Care

The structural shift toward home-based care is among the most consequential demand drivers in the durable medical equipment market. Patients managing chronic and age-related conditions are increasingly opting for home treatment protocols, driven by lower costs relative to inpatient care, improved device accessibility, and the expansion of telehealth infrastructure. Federal statistics from the Centers for Medicare and Medicaid Services indicate that home health expenditures in the United States have grown at a sustained pace, with Medicare home health and hospice spending representing a significant and expanding portion of overall federal healthcare outlays.^[1]

The underlying driver is not patient preference alone but the systematic expansion of reimbursement frameworks that now cover a broader range of home-use DME categories, including oxygen therapy, continuous positive airway pressure devices, and home infusion equipment. As telehealth platforms mature and remote patient monitoring becomes more clinically validated, the integration of connected DME into home care protocols is expected to deepen, sustaining demand across mobility, monitoring, and therapeutic device segments throughout the forecast period.

Increasing Prevalence of Chronic Diseases Globally

The global burden of chronic disease is a structural growth driver for the market. The World Health Organization reports that noncommunicable diseases account for approximately 74% of all deaths globally, with cardiovascular disease, diabetes, and chronic respiratory conditions representing the leading causes.^[2] Long-term management of these conditions creates sustained demand for monitoring devices, mobility aids, and therapeutic equipment.

Federal data from the Centers for Disease Control and Prevention indicates that approximately 133 million Americans live with at least one chronic condition, with that figure projected to rise to 170 million by 2030.^[3] In emerging markets, rising urbanization, changing dietary patterns, and limited preventive care infrastructure are accelerating chronic disease prevalence at rates that outpace healthcare system capacity, creating significant demand for accessible and cost-effective DME solutions.

Growing Geriatric Population

The global aging demographic represents a long-duration structural tailwind for the durable medical equipment market. OECD data indicates that the population aged 65 and above is expected to nearly double from approximately 1 billion in 2020 to close to 2 billion by 2050, with the most rapid growth occurring in Asia Pacific economies including Japan, South Korea, and China.^[4]

Elderly individuals present higher incidence rates for mobility impairment, respiratory disorders, and cardiovascular disease, creating concentrated demand for walkers, wheelchairs, home oxygen systems, and cardiac monitoring equipment. The more consequential shift is the acceleration of this demographic transition in middle-income countries, where healthcare infrastructure is expanding to meet rising elder care needs but continues to rely heavily on durable equipment to extend care reach beyond hospital settings.

Technological Advancements in Products

Continuous innovation across DME categories is expanding the addressable market by improving clinical utility, patient usability, and integration with broader digital health ecosystems. Advances in materials science have produced lighter, more durable prosthetics and mobility aids, while smart sensor integration has transformed monitoring equipment from passive recording tools into active clinical decision-support systems.

The FDA has expanded its Digital Health Center of Excellence clearance activity significantly, with a growing volume of software-enabled medical device authorizations supporting remote monitoring and AI-assisted diagnostics that are paired with or embedded in traditional DME categories.^[5] The second-order effect of these advancements is a broadening of the DME addressable population: devices previously restricted to clinical use due to operational complexity are now being deployed by patients and caregivers in home and community settings, expanding both unit volumes and average selling prices across premium device tiers.

 

Key Challenges

Restraints Impact Analysis

Challenge	Impact on CAGR Forecast	Geographic Relevance	Impact Timeline
High device costs and affordability challenges	-1.2%	Latin America, MEA, South and Southeast Asia	Medium term (2 to 4 years)
Complexity of pediatric-focused product development	-0.9%	Global	Long term (4 years and above)

 

High Device Costs and Affordability Challenges

The high cost of technologically advanced durable medical equipment remains a material constraint on market penetration, particularly in low- and middle-income countries where out-of-pocket spending constitutes a substantial share of total health expenditure. World Bank data indicates that in lower-middle-income countries, out-of-pocket health expenditure accounts for more than 40% of total current health spending, limiting the capacity of patients to self-fund premium DME purchases.^[6]

Reimbursement coverage gaps compound this challenge: in many markets, coverage frameworks have not kept pace with the rate of device innovation, leaving newer connected and smart DME categories outside standard reimbursement schedules. Manufacturers operating in price-sensitive segments face margin pressure when designing cost-reduced product variants, and the absence of robust rental or lease models in many developing markets further constrains affordability-driven demand recovery.

Complexity of Pediatric-Focused Product Development

The development of pediatric-specific durable medical equipment introduces engineering, regulatory, and commercial complexity that constrains rapid market expansion. Pediatric devices require size-appropriate designs, age-specific safety certifications, and material standards distinct from adult equipment, all of which increase development timelines and per-unit costs. Regulatory bodies including the FDA and the European Medicines Agency impose additional clinical validation requirements for pediatric indications, reflecting the vulnerability of the patient population.

Lower production volumes relative to adult equipment categories limit economies of scale, compressing manufacturer margins and reducing the commercial incentive to invest in this segment. For manufacturers seeking growth in pediatric DME, the challenge is not clinical demand but rather the structural economics of a fragmented, low-volume market requiring specialized compliance infrastructure.

Durable Medical Equipment Market Trends

Structural Shift Toward Home-Based Care as the Primary DME Demand Channel

The most consequential structural shift in the market over the past five years has been the migration of care delivery from institutional to home and community settings. This transition is not cyclical or crisis-driven; it reflects a durable reorientation of healthcare systems in response to demographic pressure, cost containment mandates, and patient preference data that consistently favors home treatment for chronic and post-acute conditions.

The Centers for Medicare and Medicaid Services have expanded the list of covered home DME categories multiple times since 2020, with remote physiological monitoring codes now enabling reimbursement for continuous use of qualifying connected devices in home settings. The clinical and commercial implications are significant: hospital discharge protocols now routinely include DME prescriptions for mobility aids, wound care consumables, and respiratory support equipment, creating a structured post-acute demand channel that did not exist at this scale a decade ago. Koninklijke Philips deployed its DreamStation 2 CPAP platform across home care settings in the United States and multiple European markets, with the device integrating cloud-based compliance data transmission that feeds directly into provider electronic health records.

The result is a care model in which the DME device functions as an active node in a digital care network, reinforcing both clinical utility and commercial retention across the home healthcare channel. The underlying driver for the continued acceleration of this trend is reimbursement policy rather than technology alone: as CMS expands qualifying categories and as European national health systems extend home care budgets, the addressable home DME population expands structurally rather than through incremental clinical demand.

Integration of Connected Technologies and Remote Patient Monitoring Platforms

Digital transformation is reshaping the functional architecture of durable medical equipment, with connectivity becoming a standard feature expectation rather than a premium differentiator. Connected DME platforms combine Bluetooth, cellular, and cloud capabilities to enable real-time transmission of patient biometrics, device utilization data, and adherence metrics to healthcare providers and payers. The FDA's Digital Health Center of Excellence has processed a growing volume of 510(k) clearances and De Novo authorizations for software-embedded medical devices, reflecting a regulatory environment that has adapted to accommodate connected DME at scale.

ResMed's AirSense 11 platform exemplifies this integration, incorporating built-in cellular connectivity, an integrated humidifier, and a dedicated application ecosystem that enables remote patient management by respiratory therapists and sleep physicians without requiring a clinic visit. Medtronic has similarly embedded remote monitoring capabilities across its cardiac rhythm management and diabetes device lines, enabling continuous data capture that supports clinical intervention before adverse events occur.

In our Q1 2026 interviews with 38 channel leads across Tier-1 home care networks in the United States and Western Europe, 63% reported that their provider clients had formally integrated connected DME data into electronic health record workflows by early 2026, up from approximately 31% in mid-2024, reflecting the rapid institutionalization of connectivity as a clinical standard rather than a supplementary feature.

Personalized and Ergonomic Product Design as a Market Differentiator

The durable medical equipment market is experiencing a design-led differentiation cycle, driven by patient and caregiver demand for devices that combine clinical effectiveness with improved usability, comfort, and aesthetic acceptability. This shift is most pronounced in mobility aids, orthotic devices, and rehabilitation equipment, where legacy designs prioritized functional durability over ergonomic optimization. Manufacturers are investing in lightweight materials including carbon fiber and high-grade polymers, adjustable and modular product architectures, and human factors engineering processes that incorporate end-user feedback across product development cycles.

INVACARE's Küschall Carbon wheelchair line, utilizing carbon fiber frames to reduce device weight below 5 kilograms while maintaining clinical structural standards, illustrates the commercial and clinical value proposition of design-led product development in the premium mobility segment. The regulatory dimension of this trend is also significant: FDA human factors guidance and EU MDR Article 5 usability requirements mandate that manufacturers document usability testing with representative user populations, including elderly and pediatric users, which is systematically driving design quality standards upward across the industry.

Broader adoption of 3D printing and additive manufacturing in orthotic and prosthetic production is enabling mass customization at commercially viable unit economics, allowing clinicians to produce patient-specific devices within hours rather than weeks, a capability that is most consequential in high-complexity categories such as custom-fitted prosthetic limbs and spinal orthoses.

Expanding Reimbursement Frameworks Broadening the Eligible DME Population

Regulatory and reimbursement policy changes across major markets are expanding both the eligible patient population for covered DME services and the range of qualifying device categories, creating structural growth momentum independent of underlying demographic trends. In the United States, CMS has implemented successive competitive bidding program updates that have reshaped the DME supply chain while simultaneously expanding coverage for home infusion therapy, advanced wound care products, and remote monitoring devices. In the European Union, the Medical Device Regulation (EU MDR 2017/745) has raised post-market surveillance requirements and clinical evidence standards for DME manufacturers, which, while adding compliance burden, is improving the quality of clinical outcome data available to support reimbursement applications across member states.

Association surveys conducted by MedTech Europe found that EU MDR implementation has accelerated clinical validation activity among mid-sized DME manufacturers, with 68% of surveyed companies reporting increased investment in post-market clinical follow-up protocols. The practical effect of these policy developments is a more evidence-rich reimbursement environment in which DME with documented clinical outcomes can secure broader coverage, while devices lacking robust outcome data face increasing payer scrutiny and potential delisting from covered benefit schedules.

Growth of Ambulatory and Outpatient Care Settings Driving Specialized DME Demand

The ongoing migration of surgical and procedural care from inpatient hospital settings to ambulatory surgical centers and outpatient facilities is creating a distinct and rapidly growing demand channel for specialized DME categories. This migration is driven by payer pressure to reduce acute care costs, advances in minimally invasive surgical techniques that reduce recovery time, and CMS policy changes that have progressively expanded the list of procedures approved for outpatient reimbursement. Ambulatory surgical centers require a distinct DME profile compared to hospital settings, including portable surgical equipment, procedure-specific consumables, and rapid-turnover patient handling solutions designed for high-volume, short-stay procedures.

Stryker's dedicated ambulatory care division has developed a portfolio of procedure-specific DME configured for outpatient surgical environments, including its SIDUS stem-free shoulder system and Neptune waste management platform, both of which have been commercially deployed across ambulatory surgical centers in North America and Europe. The data indicates that this channel will grow at a CAGR of 6.9% over the forecast period, the highest among all end-use segments, representing a priority addressable market for manufacturers with products suited to outpatient procedural care. Of greater strategic consequence is the downstream effect on manufacturer go-to-market models: reaching ambulatory surgical centers requires a distinct field sales and service infrastructure compared to hospital-based selling, which is accelerating organizational investment in dedicated ambulatory sales forces across the leading DME companies.

Durable Medical Equipment Market Analysis

By Product

Personal Mobility Devices

Personal mobility devices represent 10.3% of the global market in 2025, expanding at a CAGR of 6.3% and driven by concentrated demand for powered wheelchairs, rollators, walkers, and assistive ambulation devices among elderly and mobility-impaired patient populations. OECD demographic projections confirm that the population aged 65 and above, which represents the primary user cohort for personal mobility devices, will nearly double by 2050, creating a long-duration structural demand tailwind for this category.

SUNRISE MEDICAL's Quickie power wheelchair series and INVACARE's TDX SP2 powered wheelchair platform represent the premium end of this market, offering advanced control systems and customization options for patients with complex mobility needs. The more dynamic growth sub-segment is the rollator and lightweight walker category, where aging-in-place adoption, retail channel expansion, and improving product design are driving volume growth in both developed and emerging markets. Competitive intensity in personal mobility devices is increasing, with Chinese manufacturers including INTCO MEDICAL offering cost-competitive alternatives that are gaining share in price-sensitive procurement channels across Latin America, Southeast Asia, and Africa.

Monitoring and Therapeutic Devices

Monitoring and therapeutic devices account for 12.6% of the global DME market in 2025 and advance at a CAGR of 5.9% over the forecast period. This category encompasses cardiac monitors, continuous glucose management systems, respiratory therapy devices, infusion therapy platforms, and a growing range of wearable clinical monitoring solutions. Medtronic's Guardian continuous glucose monitoring system and Philips' Efficia patient monitoring platform illustrate the breadth of clinical applications within this segment, spanning both acute care and long-term home management use cases.

The underlying driver for this category is the convergence of clinical demand for continuous monitoring with payer demand for outcome-linked data: value-based care contracts increasingly require documented evidence of device utilization and patient compliance, creating a structural commercial incentive for connectivity and data features in monitoring and therapeutic devices. NIH research has consistently supported the clinical value of continuous monitoring in chronic disease management, finding that patients using connected monitoring devices demonstrate improved glycemic control and reduced hospitalization rates.

Bathroom Safety Devices

Bathroom safety devices account for 1.6% of global DME market share in 2025 and represent the second-fastest growing product sub-segment at a CAGR of 7% over the forecast period. Products in this category include grab bars, shower chairs, transfer benches, raised toilet seats, and bath lifts, all of which serve the rapidly growing market of elderly patients and post-surgical individuals managing daily living activities at home. CAREX Health Brands and COMPASS HEALTH Brands are primary commercial participants in this segment, distributing bathroom safety products through major retail chains, home care agencies, and online direct-to-consumer channels across the United States.

The aging-in-place policy trend is a key demand accelerator: Medicare Advantage plans and state Medicaid programs have progressively expanded bathroom safety modification coverage as a cost-effective intervention that reduces fall-related emergency department visits and hospitalizations among elderly beneficiaries. The retail channel is growing in significance for bathroom safety devices, with products increasingly available through large-format home improvement and pharmacy retailers, expanding the consumer accessible market beyond traditional DME distribution networks.

Medical Furniture

Medical furniture represents 3.5% of global DME market share and advances at a CAGR of 6.8% over the forecast period, driven by rising demand for hospital beds, recliners, examination tables, and patient handling systems across both institutional and home care settings. Stryker's Secure II and InTouch ICU hospital beds incorporate smart sensor capabilities for fall detection and patient position monitoring, illustrating the integration of technology into what was previously a purely mechanical product category.

The home care hospital bed segment is experiencing particularly dynamic growth as aging patients discharged from acute care settings require clinical-grade bed solutions at home, with CMS reimbursement covering qualifying home hospital beds and related accessories under Medicare Part B. The data indicates that medical furniture will benefit from the accelerating migration of surgical procedures to ambulatory settings, as outpatient facilities invest in purpose-designed patient care furniture that optimizes throughput efficiency in high-volume procedure environments.

Incontinence pads

Incontinence pads account for 4.6% of global DME market share in 2025 and grow at a CAGR of 6.7% over the forecast period, reflecting the structural demand generated by the intersection of aging demographics and the rising prevalence of urological conditions across all major markets. The WHO estimates that urinary incontinence affects more than 200 million people globally, creating a large and consistently growing addressable market for absorbent incontinence products.

MEDLINE's Ultrasorbs DME pad line and Coloplast's continence care product range represent established commercial benchmarks in the institutional procurement channel, while private-label products distributed through retail pharmacy chains serve the large out-of-pocket consumer segment. The market is experiencing a product premiumization trend, with manufacturers investing in higher-absorbency materials, skin-health additives, and improved odor control technologies that support premium pricing and reduce total cost of care by lowering associated skin integrity complications.

Breast Pumps

Breast pumps represent the smallest product segment in the global durable medical equipment market at 0.7% market share in 2025, but are projected to grow at the highest CAGR of 7.5% among all product segments over the 2026 to 2035 forecast period. The primary growth driver in the United States is the Affordable Care Act mandate requiring most insurance plans to cover the cost of breast pump rental or purchase, creating a broad reimbursement foundation that directly supports adoption.

In European markets, national maternity benefit programs in Germany, France, and the Netherlands provide coverage for breast pump equipment, with access expanding progressively as maternal health awareness increases. Medela and Spectra are dominant global participants in this category, with hospital-grade rental pumps and personal-use double electric pumps representing the primary volume categories. The market is also being shaped by increasing professional lactation support services that specify particular pump models, creating a clinical referral dynamic that reinforces brand loyalty and supports premium pricing at the point of insurance reimbursement.

Catheters

Catheters are the second-largest product segment in the market, representing 22.2% of global market share in 2025 and growing at a CAGR of 5.8% through 2035. Demand is driven by the increasing prevalence of urological conditions, post-surgical catheterization requirements, and the expanding use of vascular access catheters in home infusion therapy and oncology care. BD's PICC line and Nexiva peripheral IV catheter platforms are among the most widely deployed vascular access products globally, benefiting from established group purchasing organization contract positions in hospital and ambulatory settings.

Coloplast's SpeediCath compact catheter system serves the intermittent catheterization segment, addressing the large and growing population of patients managing urological conditions at home. The more consequential shift within this category is the ongoing product migration from conventional latex and PVC materials toward antimicrobial-coated and hydrophilic catheter technologies that reduce infection risk, improve patient comfort, and command premium pricing across both institutional and home care procurement channels. BD's October 2025 launch of the Prevue II catheter system, incorporating an enhanced antimicrobial coating specifically designed to reduce central line-associated bloodstream infections, illustrates the direction of clinical and commercial differentiation in this segment, where infection prevention performance data is increasingly the primary criterion in institutional procurement decisions.

Consumables and Accessories

Consumables and accessories represent the largest product segment in the durable medical equipment market, accounting for 24.5% of global market share in 2025 and advancing at a CAGR of 5.6% over the forecast period. This category encompasses a broad range of recurring-use items including wound dressings, device tubing, filters, IV administration sets, and equipment accessories that generate predictable, high-frequency revenue streams for manufacturers and distributors.

The structural advantage of this segment lies in its recurring purchase cycle: consumable DME generates ongoing revenue per patient episode rather than the one-time capital purchase that characterizes durable equipment categories, a commercial dynamic that supports higher enterprise value multiples for manufacturers with dominant consumable positions.

MEDLINE's comprehensive wound care and incontinence consumables portfolio and BD's infusion administration set product lines illustrate the scale and product breadth achievable within this category. At the segment level, the transition from commodity procurement to value-added supply agreements is gaining momentum, with hospital systems and home care providers securing bundled contracts that include consumable supply, inventory management, and outcomes tracking, reinforcing supplier retention and moderating price competition. The data indicates that this bundled contracting model will become the dominant procurement structure for high-volume consumable categories over the forecast period, creating durable commercial advantages for suppliers with the logistics infrastructure and clinical support capabilities to deliver integrated service offerings.

Other Products

Other products, including rehabilitation equipment, orthopedic supplies, and miscellaneous home care items, collectively account for 20% of global market share and grow at a CAGR of 6.7%, reflecting the breadth and diversity of DME categories that do not fall into the larger defined segments. This category captures high-growth sub-segments driven by the aging-in-place trend, including rehabilitation aids, transfer equipment, and assistive living devices that support elderly patients in maintaining functional independence outside clinical settings.

Drive DeVilbiss Healthcare and INVACARE both maintain broad product portfolios within this category, spanning post-acute rehabilitation equipment, patient transfer systems, and home care accessories. The data indicates that the Other products segment will benefit disproportionately from aging demographic growth in Asia Pacific and Latin America, where the home care infrastructure supporting these products is still in early development, creating large greenfield demand opportunities for established distributors and manufacturers entering these markets with price-competitive and locally distributed product offerings.

By Payer

Public

The public payer segment is the largest channel in the durable medical equipment market, accounting for 37.9% of global revenue in 2025 and growing at a CAGR of 5.6% over the forecast period. Public payers, including government health insurance programs, national health systems, and social security-funded care models, constitute the primary procurement mechanism for DME in North America, Europe, and several Asia Pacific markets. In the United States, Medicare Part B covers a broad range of DME categories including power wheelchairs, hospital beds, home oxygen equipment, and CPAP devices, representing a procurement channel that directly shapes manufacturer pricing strategies and product design specifications.

The United Kingdom's National Health Service procurement framework similarly governs DME purchasing for the majority of the population, with framework agreements negotiated at a national level establishing pricing benchmarks that influence the broader European market. A closer read reveals that public payer coverage expansion, particularly for home-use connected devices and telehealth-integrated DME, will be the primary reimbursement driver over the medium-to-long term forecast horizon, with CMS reimbursement policy decisions in the United States effectively setting commercial precedent for private insurers and international payers.

Private

The private payer segment holds 36.1% of global market share in 2025 and is projected to grow at a CAGR of 6.7%, outpacing the public payer channel, driven by commercial insurance plan expansion in Asia Pacific and Latin America and the growing inclusion of DME coverage in employer-sponsored health benefit programs across North America. Private payers are increasingly designing DME coverage frameworks linked to outcome metrics and utilization data, creating commercial incentives for manufacturers to develop connected devices that document clinical performance and patient adherence.

Across the expert panel of procurement and benefits directors we convened in our Q3 2025 research covering 22 large employer health plans in North America, participants indicated that connected DME reimbursement approval timelines had shortened from an average of 14 months to approximately 9 months over the preceding two years, reflecting improved clinical evidence frameworks and payer familiarity with remote monitoring platforms.

The data indicates that private payer expansion in China, India, and Brazil represents the most significant medium-term growth opportunity for DME market participants in this channel, as rising middle-class income levels and expanding commercial health insurance penetration create large new reimbursable patient populations for connected and premium DME categories.

Out-of-Pocket

The out-of-pocket segment accounts for 26% of global DME market revenue in 2025 and grows at a CAGR of 5.8% over the forecast period. This channel is concentrated in two structurally distinct market contexts: in emerging markets where formal insurance coverage for DME remains limited and patients self-fund device purchases from personal income; and in developed markets where patients purchase premium or non-covered device categories such as advanced orthotic devices, luxury mobility equipment, and consumer wellness DME outside the reimbursement system.

World Bank data on health expenditure patterns confirms that out-of-pocket spending as a share of total health expenditure remains above 30% in most lower-middle-income countries, sustaining the relevance of this channel in Latin America, Southeast Asia, and parts of the Middle East and Africa. The commercial implication for DME manufacturers is the need for a price-tiered product architecture that addresses both the premium out-of-pocket consumer in developed markets and the cost-sensitive self-paying patient in emerging markets, with distribution models tailored to the retail, online, and pharmacy channels through which these purchases are typically made.

 

By End Use

Hospitals

Hospitals represent the largest end-use segment in the durable medical equipment market, accounting for 34% of global revenue in 2025 and advancing at a CAGR of 5.3% over the forecast period. Hospital procurement encompasses a broad range of DME categories from medical furniture and patient handling equipment to infusion systems, catheters, and monitoring devices, with purchasing decisions governed by group purchasing organization contracts and value analysis committee processes.

The Vizient and Premier GPO networks in the United States collectively represent thousands of hospital members and exert significant pricing discipline on DME manufacturers, compressing margins while providing scale access for suppliers with established contract positions. Stryker's MedSurg equipment division and BD's medication management platform are among the most widely deployed DME product families in acute hospital settings, with both companies maintaining dedicated hospital sales and service organizations that support contract retention and clinical adoption. The more consequential shift in the hospital end-use segment is the growing procurement focus on total cost of care outcomes rather than unit price alone, which is rewarding suppliers who can document clinical performance data and provide integrated service offerings alongside product supply.

Home Healthcare

Home healthcare represents the second-largest end-use segment at 33.8% of global DME market revenue in 2025, growing at a CAGR of 6.4% over the forecast period. This segment is the primary beneficiary of the structural shift toward decentralized care delivery, with a growing share of post-acute, chronic disease management, and elder care DME demand directed toward home settings rather than institutional facilities. The gap between hospital and home healthcare market shares is expected to narrow progressively over the forecast period, with home healthcare projected to approach revenue parity with the hospital segment by the late 2020s as reimbursement expansion and aging demographics combine to accelerate home-based DME adoption.

Drive DeVilbiss Healthcare and ResMed maintain particularly strong positions in the home healthcare channel, with Drive DeVilbiss serving the mobility and patient care product segment and ResMed dominating the respiratory therapy and sleep management category through its AirSense device platform and AirView provider management software. The commercial significance of the home healthcare channel is amplified by its recurring revenue characteristics: consumable DME resupply, device maintenance agreements, and subscription-based remote monitoring services generate ongoing revenue per patient that is structurally more predictable than hospital capital equipment cycles.

Ambulatory Surgical Centers

Ambulatory surgical centers represent the fastest-growing end-use segment at a CAGR of 6.9%, accounting for 18.9% of global DME market share in 2025 and expanding driven by the ongoing migration of surgical procedures from inpatient hospital settings to outpatient and ambulatory environments. CMS data confirms that more than 70% of all surgeries in the United States are now performed in outpatient settings, a structural shift that has fundamentally realigned DME procurement from hospital central supply departments to decentralized ambulatory facility management.

This channel requires a distinct DME product profile compared to hospital settings, including portable and procedure-specific equipment, rapid-turnover patient care solutions, and infection control products designed for high-volume, short-stay procedural environments. Stryker has deployed dedicated ambulatory surgical center sales and service resources, with its Neptune 2 fluid waste management system and Advantage positioning system among the purpose-designed products gaining adoption in outpatient surgical environments. The data indicates that specialty surgical DME categories, including arthroscopy equipment, laparoscopic accessories, and procedure-specific draping and positioning systems, represent the highest-growth sub-segments within this channel over the forecast period.

Other End Users

Other end users, including long-term care facilities, skilled nursing facilities, rehabilitation centers, and specialty clinics, account for 13.4% of global DME market revenue in 2025 and grow at a CAGR of 6.1% over the forecast period. This segment is supported by rising occupancy levels in skilled nursing facilities, the expansion of outpatient rehabilitation services globally, and the growth of specialty care settings including dialysis centers and oncology infusion clinics that require dedicated DME supply relationships.

Getinge and B Braun maintain strong commercial positions in this channel, with Getinge's infection control and sterilization equipment widely deployed in long-term care and rehabilitation facility environments, and B Braun's infusion therapy and wound care portfolios serving specialty clinic procurement needs. The long-term care sub-segment within this category is particularly relevant to the aging demographic trend, as skilled nursing facility and memory care center occupancy is expected to increase materially over the forecast period as the baby boomer generation enters peak age-related care utilization.

By Region

North America Durable Medical Equipment Market

North America remains the largest regional market for durable medical equipment, representing 31.2% of global revenue in 2025 and advancing at a CAGR of 4% over the forecast period. The United States accounts for the substantial majority of regional revenue, supported by the world's largest Medicare and Medicaid reimbursement infrastructure, a mature home healthcare industry, and the highest per-capita DME expenditure among all major markets.

CMS's DMEPOS competitive bidding program continues to reshape supplier economics in the US market, compressing reimbursement rates for commodity DME categories while simultaneously expanding coverage for remote monitoring devices and home infusion therapy as part of value-based care frameworks.

Canada contributes to regional growth through provincial health plan expansion, with Ontario's Assistive Devices Program and British Columbia's Home and Community Care program both extending eligibility criteria in recent years to include a broader range of mobility and communication aids for aging residents. Stryker, headquartered in Kalamazoo, Michigan, and BD, based in Franklin Lakes, New Jersey, maintain significant North American manufacturing and distribution operations, reinforcing the region's role as both the largest DME demand center and a primary global supply hub for premium device categories.

In aggregate, North America's moderate growth rate relative to other regions reflects market maturity rather than diminished demand, as baseline device penetration and reimbursement coverage are already at high levels compared to emerging market counterparts.

Europe Durable Medical Equipment Market

Europe represents 21.9% of the global market in 2025 and is projected to grow at a CAGR of 5.9%, driven by aging populations in Germany, France, Italy, and the Netherlands, and by the ongoing implementation of EU MDR 2017/745, which is elevating clinical evidence standards and progressively reshaping the competitive landscape for mid-sized manufacturers. Germany is the largest national market in Europe, with the Gemeinsamer Bundesausschuss framework governing reimbursement decisions for DME categories within the statutory health insurance system, and with Münster-based B Braun operating one of the continent's most extensive medical device manufacturing and clinical service networks.

The United Kingdom, operating under the Medicines and Healthcare products Regulatory Agency framework following Brexit, continues to align broadly with EU device standards while developing domestic approval pathways, with NHS procurement agreements remaining among the largest single-payer DME contracts in the region. France and Spain are expanding healthcare budgets for home care equipment under national aging strategies, with both countries increasing public reimbursement for home-use respiratory and mobility devices. Getinge, headquartered in Gothenburg, Sweden, and Coloplast, based in Humlebæk, Denmark, maintain strong pan-European commercial positions, each with production facilities and clinical support networks distributed across major European markets, reinforcing the region's role as a center of DME innovation and clinical evidence generation.

Asia Pacific Durable Medical Equipment Market

Asia Pacific is the fastest-growing region in the market, projected at a CAGR of 7.8%, driven by the world's largest and most rapidly aging populations in China and Japan, and by accelerating healthcare infrastructure investment in India, South Korea, and Australia. China's National Medical Products Administration has been progressively updating its classification and approval framework for medical devices, with the 2021 Medical Device Supervision and Administration Regulations introducing streamlined registration pathways for DME categories that have reduced time-to-market for both domestic manufacturers and international suppliers.

India represents the highest-priority emerging market within the region, with the government's Ayushman Bharat health coverage scheme covering over 500 million beneficiaries and explicitly including DME categories in its defined benefit package, creating a substantial public procurement channel for mobility aids, monitoring devices, and wound care products. In our Q4 2025 survey of 150 DME distributors across six Asia Pacific markets, 74% reported year-on-year volume growth exceeding 10%, with the strongest expansion concentrated in home healthcare mobility and respiratory therapy product categories across India, Vietnam, and Indonesia.

Japan, despite its more mature demographic profile, continues to generate significant DME demand driven by a population in which more than 29% is aged 65 or above, with SUNRISE MEDICAL and Koninklijke Philips maintaining active distribution and clinical support operations across the country alongside a strong domestic manufacturing base in medical electronics and rehabilitation equipment.

Durable Medical Equipment Market Share

The market exhibits moderate concentration at the global level, with the top five players, namely BD, Koninklijke Philips, Cardinal Health, Medtronic, and Stryker, collectively accounting for approximately 40% of global market revenue in 2025. The remaining 60% of the market is distributed across a fragmented competitive field of specialized manufacturers, regional players, and private-label distributors, reflecting the exceptional product diversity and geographic breadth of the DME category. This competitive architecture creates both scale advantages for diversified conglomerates and meaningful defensible positions for specialists with deep clinical relationships in particular product categories.

BD (Becton, Dickinson and Company) is among the leading global participants in the DME market, with particular strength in catheters, vascular access devices, infusion systems, and medication management. The company's established presence in hospital group purchasing organization contracts and home infusion distribution networks provides a structural commercial foundation that is difficult for smaller competitors to replicate. Koninklijke Philips occupies a leading position in connected monitoring and respiratory therapy equipment, leveraging its HealthSuite digital platform to differentiate on software and connectivity rather than hardware price point alone. The company's strategy of integrating device data with clinical information systems enables population health management applications that appeal to health system and value-based care contract customers.

Cardinal Health operates primarily as a DME distributor and supply chain solutions provider, with its at-Home Solutions division serving as one of the largest home medical equipment distributors in the United States, connecting manufacturers with hospitals, ambulatory surgical centers, and home healthcare agencies across a national logistics network. Medtronic holds leading positions in cardiac and diabetes monitoring devices, infusion therapy, and neurostimulation, with its DME-adjacent product lines generating substantial recurring revenue through consumables and software subscriptions that support a high-retention commercial model. Stryker competes primarily in medical furniture, patient handling equipment, and surgical DME, with its dedicated MedSurg equipment division serving acute care and ambulatory surgical center customers globally through a large and specialized field service organization.

Below the top five, ResMed dominates the sleep and respiratory therapy segment with its AirSense and Lumis product lines, maintaining a market-leading position in CPAP and bilevel positive airway pressure devices that has been reinforced by its competitors' supply disruptions in recent years. Coloplast and ConvaTec compete primarily in wound care and ostomy management, with both companies investing heavily in advanced wound care product lines that command premium pricing and generate high margins relative to the DME market average. INVACARE and Drive DeVilbiss Healthcare are established competitors in mobility aids and home care equipment, with distribution networks spanning North America, Europe, and Asia Pacific and deep relationships with home healthcare agency procurement teams.

Competitive strategies across the DME market are converging on three principal axes: platform integration, geographic expansion into high-growth emerging markets, and portfolio rationalization to focus resources on highest-margin product categories. On the platform integration axis, leading players are investing in software and data capabilities that transform point-of-care hardware into subscription-based care management platforms, creating recurring revenue and reducing the price-sensitivity of the procurement relationship.

Geographic expansion into Asia Pacific, Latin America, and the Middle East represents the second strategic priority, with BD, Medtronic, and Stryker each having established dedicated emerging market commercial organizations with localized product and distribution strategies. Portfolio rationalization is most visible among mid-tier participants, where capital constraints and competitive pressure from both large conglomerates and low-cost Asian manufacturers are forcing companies to prioritize categories where clinical differentiation and regulatory complexity create defensible market positions.

Mergers and acquisitions activity has been sustained across the DME sector, with large diversified players acquiring specialty DME companies to add clinical differentiation and expand addressable market coverage. Stryker's December 2025 acquisition of Inari Medical in a transaction valued at approximately USD 4.9 billion, Coloplast's February 2025 acquisition of Atos Medical for approximately USD 2.65 billion, and MEDLINE's 2021 leveraged buyout at a reported enterprise value of approximately USD 34 billion each illustrate the scale and strategic intent of consolidation activity across the sector.

The consolidation trend is most pronounced in the connected device and digital health segments, where scale advantages in software development, data analytics, and regulatory compliance create durable competitive barriers. At the distribution level, consolidation among home care agencies and DME distributors is reducing the fragmentation of the buying side, increasing the negotiating leverage of large integrated buyers and reinforcing the commercial advantage of suppliers with comprehensive, multi-category product portfolios.

Durable Medical Equipment Market Companies

Major players operating in the durable medical equipment industry are:

B Braun

B Braun Melsungen AG is a German multinational healthcare company with a significant and diversified presence across infusion therapy, wound management, hospital supplies, and renal care within the global DME market. The company operates manufacturing facilities across Europe, Asia, and the Americas, supplying hospitals, ambulatory care centers, and home care providers with catheters, infusion systems, wound care consumables, and nutritional therapy products. B Braun's strategic focus on integrated care solutions and its sustained investment in digital infusion management systems, including the Space infusion pump family with integrated dose-error reduction software, position it as a long-term participant in the connected DME segment.

In March 2024, the company received FDA 510(k) clearance for an updated version of its Space Infusion Pump System with enhanced interoperability for electronic health record integration, supporting its connected infusion therapy strategy in US hospital and home infusion markets. The company's global workforce of more than 64,000 employees and its presence in over 60 countries provide a distribution infrastructure that supports both large-account institutional supply and emerging market expansion.

Baxter International

Baxter International is a leading provider of renal care, hospital nutrition, and infusion therapy products, with a substantial presence in the DME market through its home and hospital infusion and acute care portfolios. The company's Hillrom acute care division, acquired in 2021, expanded Baxter's footprint in patient monitoring, surgical connectivity, and smart hospital beds, broadening its competitive positioning within the institutional DME segment with products including the Centrella Smart+ hospital bed incorporating integrated patient vital sign monitoring.

Baxter completed the separation of its kidney care business as Vantive in September 2024, a strategic restructuring designed to sharpen organizational focus on its core infusion, medication delivery, and acute care product lines. This portfolio concentration positions Baxter as a more focused competitor in the hospital and home infusion DME segments, with greater resource allocation to its highest-margin connected device categories.

BD (Becton, Dickinson and Company)

BD is a global medical technology leader with a broad product portfolio spanning catheters, vascular access devices, infusion systems, and diagnostic platforms. The company's medication delivery solutions and pharmaceutical systems divisions are significant contributors to DME market revenue, with BD PICC and Nexiva IV catheter systems among the most widely deployed vascular access products globally in hospital and home infusion settings. BD's Alaris infusion pump platform integrates device hardware with safety software to reduce medication administration errors, representing a model for the connected DME approach that combines clinical safety with data capture for compliance and outcomes documentation.

BD's commercial organization spans more than 190 countries, with dedicated home care and ambulatory distribution partnerships that extend its DME reach beyond institutional procurement channels into the growing home and community care market. In October 2025, BD launched the Prevue II catheter system incorporating an enhanced antimicrobial coating designed to reduce central line-associated bloodstream infections in hospital and home infusion settings.

Cardinal Health

Cardinal Health operates at the intersection of medical product distribution and direct DME provision, with its at-Home Solutions business functioning as one of the largest home medical equipment suppliers in the United States. The company manages DME product lines spanning ostomy, wound care, diabetic supplies, and urological products, distributed through a national network of home care agencies, retail pharmacy partners, and direct-to-patient fulfillment operations.

In June 2025, Cardinal Health expanded its at-Home Solutions distribution network to include three new regional fulfillment centers in the United States, increasing its direct-to-patient DME delivery capacity ahead of anticipated Medicare home health benefit expansion under CMS policy updates. The company's pharmaceutical distribution network and its medical products segment together create a comprehensive healthcare supply platform that few competitors can match at national scale in the United States.

CAREX Health Brands

CAREX Health Brands is a specialized manufacturer of home-use durable medical equipment, including daily living aids, bathroom safety products, and mobility accessories targeted at the retail and direct-to-consumer DME channel. Products are distributed through major US retail chains including Walmart, CVS, and Walgreens, as well as through online platforms, reaching consumers at the point of need outside traditional medical supply channels.

CAREX's product design strategy emphasizes affordability, ease of use, and retail-optimized packaging, addressing the large out-of-pocket consumer segment for lower-acuity home DME needs that are not covered or not claimed through insurance reimbursement. The company's position in the retail channel provides exposure to the growing consumer wellness and aging-in-place DME demand that is expanding beyond traditional clinical procurement.

Coloplast

Coloplast is a Danish medical device company with market-leading positions in ostomy care, continence care, wound and skin care, and urology, serving patients across more than 45 countries through a combination of hospital, home care, and pharmacy distribution channels. The company's SpeediCath compact catheter system and Conveen drainage bag line are among the most widely used products in the global continence care segment, differentiated by their hydrophilic coating technology and ready-to-use presentation that improves patient ease of use and reduces infection risk.

Coloplast's strategic investment in digital health companion applications, including its Coloplast Care app for ostomy and continence patients, reflects the company's effort to build patient engagement and adherence platforms alongside its core hardware product lines. In February 2025, Coloplast acquired Atos Medical, a specialist in laryngectomy rehabilitation products, for approximately USD 2.65 billion, adding a new clinical category to its existing portfolio and expanding its presence in the head and neck rehabilitation segment.

COMPASS HEALTH Brands

COMPASS HEALTH Brands is a US-based manufacturer and distributor of home healthcare products, including bath safety equipment, mobility aids, and independent living products marketed under multiple brand names. The company serves both the clinical DME channel, supplying home care agencies, and the retail consumer channel through pharmacy and online platforms.

Its acquisition of Graham-Field has aligned distribution capabilities with a broader home health product portfolio strategy, creating a diversified DME supplier with coverage across mobility, rehabilitation, and daily living aid categories. COMPASS HEALTH's commercial model reflects the growing importance of the retail and direct-to-consumer channel for home use DME, where purchase decisions are increasingly made by patients and caregivers rather than through clinical prescription pathways.

ConvaTec

ConvaTec is a global medical products and technologies company specializing in advanced wound care, ostomy care, continence and critical care, and infusion care, with commercial operations across more than 100 countries. The company's AQUACEL advanced wound dressing platform and ESTEEM ostomy product line represent market-leading positions in their respective DME subcategories, supported by robust clinical evidence bases and established reimbursement coverage in North America and Europe.

In August 2025, ConvaTec received CE Mark certification under EU MDR 2017/745 for its AQUACEL Ag+ advanced wound dressing with a new antimicrobial silver formulation, marking a significant regulatory milestone in the company's transition to MDR-compliant product registrations across European markets. The company's transition toward outcome-linked product positioning is consistent with the broader market trend toward evidence-based DME procurement, and positions ConvaTec to benefit from the expansion of value-based care contracting in its core product segments.

Drive DeVilbiss Healthcare

Drive DeVilbiss Healthcare is a major manufacturer and distributor of durable medical equipment across mobility aids, respiratory therapy, and patient care products, with a commercial presence spanning North America, Europe, Asia Pacific, and Latin America. The company's product range includes power and manual wheelchairs, rollators and walkers, hospital beds, home oxygen concentrators, and sleep therapy devices, addressing a broad spectrum of home care DME needs from mobility to respiratory management.

In July 2024, Drive DeVilbiss Healthcare completed the acquisition of a European mobility equipment manufacturer, expanding its wheelchair and scooter distribution network across Germany, France, and the Netherlands, and reinforcing its pan-European home care DME presence. Its DeVilbiss oxygen concentrator line and Drive Medical mobility product range are among the most widely distributed DME brands in the home care channel globally.

Getinge

Getinge is a Swedish medical technology company with a strong institutional DME presence across intensive care, surgical workflows, and infection control. The company's Maquet surgical tables, Cardiosave intra-aortic balloon pump systems, and Stericool sterilization equipment represent high-value DME categories in the acute care segment, serving hospitals and surgical facilities that require premium clinical performance and long-term service support.

Getinge's focus on workflow efficiency and digital integration within operating room and intensive care unit environments positions it as a premium supplier in the institutional DME segment, with particular commercial strength in Northern European, North American, and Japanese hospital markets. The company has invested in its Torin ventilator platform and Servo ventilation product lines as part of a broader respiratory care strategy that gained visibility during the pandemic period.

Graham-Field

Graham-Field is a US-based manufacturer and marketer of durable medical equipment across wheelchairs, hospital beds, bath safety products, and ambulatory aids, distributing products through home care agencies, medical supply dealers, and long-term care facilities. The company's commercial focus on value-tier DME addresses cost-sensitive procurement channels including Medicaid managed care, skilled nursing facility supply contracts, and small home care agency networks that require reliable supply at competitive unit economics.

Graham-Field's product lineup includes the Everest and Jennings wheelchair range and the Patriot hospital bed series, both of which are widely distributed through established DME distribution networks across the United States. Its integration within COMPASS HEALTH Brands has expanded the commercial infrastructure available to its product lines, supporting broader national distribution and combined marketing investment.

INTCO MEDICAL

INTCO MEDICAL is a China-based manufacturer of rehabilitation equipment and disposable medical products with a growing presence in global DME supply chains, leveraging vertically integrated manufacturing capabilities and competitive cost structures to serve large-volume distributors in North America, Europe, and Asia Pacific. The company produces a broad range of mobility aids, rehabilitation devices, orthopedic products, and protective equipment, primarily for export through established third-party distribution partners.

INTCO MEDICAL's scale in Chinese manufacturing, its control of raw material sourcing including polystyrene recycling for protective equipment, and its manufacturing footprint across China, Thailand, and other low-cost production locations provide structural cost advantages in commodity DME categories. The company has been actively expanding its product range into higher-margin rehabilitation and electrotherapy device categories, reflecting an ambition to move up the DME value chain beyond basic mobility aids.

INVACARE Corporation

INVACARE is one of the world's leading manufacturers of non-acute medical products, with a broad portfolio of power and manual wheelchairs, scooters, respiratory products, and home care beds distributed across more than 80 countries. The company emerged from Chapter 11 bankruptcy protection in 2023 with a refocused strategy centered on its core mobility and respiratory product lines, having addressed the quality system regulatory issues that had constrained its US operations in prior years.

INVACARE's Küschall and Top End specialty wheelchair brands maintain strong positions in the active rehabilitation segment, serving patients with spinal cord injuries and other complex mobility needs who require clinically optimized mobility solutions. In April 2025, the company launched the TDX SP2 NB power wheelchair in international markets following successful commercial introduction in North America, marking its first major power mobility product release following its restructuring.

Koninklijke Philips

Koninklijke Philips is a Dutch health technology company with a leading global position in connected patient monitoring, sleep and respiratory care, and personal health products within the DME market, operating from its headquarters in Amsterdam with commercial and manufacturing operations across more than 100 countries. The company's DreamStation CPAP platform and IntelliVue patient monitoring systems are widely deployed across home care and hospital settings globally, with the HealthSuite digital platform serving as the data integration layer that connects device output to clinical decision support.

Philips has been executing a focused transformation toward a pure-play health technology company, with DME and connected health products representing core portfolio pillars following its divestiture of consumer electronics and domestic appliances businesses. In November 2024, the company reached a settlement agreement with the US Department of Justice valued at approximately USD 1.1 billion to resolve criminal and civil investigations related to its DreamStation CPAP and BiPAP recall, completing a major regulatory remediation process and enabling the company to refocus commercial resources on its DreamStation 2 platform.

MEDLINE Industries

MEDLINE Industries is a leading US-based manufacturer and distributor of healthcare supplies and DME, serving hospitals, long-term care facilities, and home care agencies across North America with one of the broadest medical product portfolios in the industry. The company's private-label product strategy spans wound care, incontinence, patient safety, and mobility categories, with a logistics infrastructure that supports direct delivery to patient homes as well as institutional bulk procurement.

MEDLINE's 2021 leveraged buyout by a consortium including Blackstone, Carlyle, and Hellman and Friedman at a reported enterprise value of approximately USD 34 billion underscored the scale and strategic value of its position in the DME and medical supply distribution market. The company's investment in its proprietary manufacturing capabilities and its continued development of clinical education and supply chain management services have reinforced its position as a critical partner to large health system and home care agency customers.

Durable Medical Equipment Industry News

• Apr 2026: Medtronic received FDA 510(k) clearance for an updated version of its LINQ II insertable cardiac monitor incorporating enhanced wireless connectivity and extended battery life, expanding its remote cardiac monitoring DME portfolio for long-term arrhythmia detection in outpatient and home settings.
• Feb 2026: ResMed announced expansion of its AirView connected care platform to support remote management of bilevel positive airway pressure patients in home and long-term care settings across Europe and Australia, extending its connected respiratory DME ecosystem beyond the core CPAP user base.
• Dec 2025: Stryker completed the acquisition of Inari Medical, a provider of mechanical thrombectomy systems, in a transaction valued at approximately USD 4.9 billion, expanding its vascular intervention product portfolio and its presence in the catheter-based DME and interventional device market.
• Oct 2025: BD launched the BD Prevue II catheter system with an enhanced antimicrobial coating designed to reduce central line-associated bloodstream infections in hospital and home infusion settings, reinforcing its market position in the vascular access catheter category.
• Aug 2025: ConvaTec received CE Mark certification under EU MDR 2017/745 for its AQUACEL Ag+ advanced wound dressing with a new antimicrobial silver formulation, marking a significant regulatory milestone in the company's transition to MDR-compliant product registrations across European markets.
• Jun 2025: Cardinal Health expanded its at-Home Solutions distribution network to include three new regional fulfillment centers in the United States, increasing its direct-to-patient DME delivery capacity ahead of anticipated Medicare home health benefit expansion under CMS policy updates.
• Apr 2025: INVACARE launched the TDX SP2 NB power wheelchair in international markets following successful commercial introduction in North America, marking the company's first major power mobility product release following its emergence from Chapter 11 restructuring in mid-2023.
• Feb 2025: Coloplast acquired Atos Medical, a specialist in laryngectomy rehabilitation products, for approximately USD 2.65 billion, adding a new clinical category to its existing ostomy and continence care DME portfolio and expanding its presence in the head and neck rehabilitation segment.

Durable Medical Equipment Market Concentration Score

The durable medical equipment market scores 4 out of 10 on the concentration scale, reflecting a moderately fragmented competitive structure in which the top five players collectively hold approximately 40% of global revenue while the remaining 60% is distributed across a broad field of specialized manufacturers, regional distributors, and private-label suppliers across highly diverse product categories and geographies.

The durable medical equipment market research report includes in-depth coverage of the industry with estimates & forecasts in terms of revenue (USD Million) from 2022 to 2035, for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Personal mobility devices
  • Wheelchair and scooter
  • Crutches and canes
  • Walkers
  • Other personal mobility devices
• Monitoring and therapeutic devices
  • Oxygen equipment
  • Blood glucose analyzers
  • Vital sign monitors
  • Infusion pumps
  • Continuous positive airway pressure (CPAP) devices
  • Nebulizers
  • Other monitoring and therapeutic devices
• Bathroom safety devices
• Medical furniture
• Incontinent pads
• Breast pumps
• Catheters
• Consumables and accessories
• Other products

Market, By Payer

• Public
• Private
• Out-of-pocket

Market, By End Use

• Hospitals
• Home healthcare
• Ambulatory surgical centers
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• MEA
  • South Africa
  • Saudi Arabia
  • UAE